ClinicalTrials.gg
CompletedNCT05102136Updated May 3, 2023

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers

A Phase 1 interventional study of REGN9933 and Placebo in Healthy Volunteers, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-03.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary objective of the study is to evaluate the safety and tolerability of single doses of REGN9933 in healthy participants

The secondary objectives of the study are to:

  • Evaluate the effects of single doses of REGN9933 on intrinsic/common pathway coagulation
  • Evaluate the effects of single doses of REGN9933 on extrinsic/common pathway coagulation
  • Characterize the drug concentration profiles and pharmacokinetic (PK) following single escalating doses of REGN9933
  • Characterize the concentration profiles of total FXI following single escalating doses of REGN9933
  • Assess the immunogenicity of single doses of REGN9933
02

Conditions studied

  • Healthy Volunteers

Keywords

  • HV
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. between 18.0 and 32.5 kilograms/per metered squared (kg/m\^2) (inclusive) at the screening visit.
  2. Judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and (ECGs) performed at screening and/or prior to administration of initial dose of study drug.
  3. Participant is in good health based on laboratory safety testing obtained at the screening visit and/or prior to administration of initial dose of study drug. Note :Participant with suspected or confirmed Gilbert's disease can be enrolled in the study.
  4. Normal (aPTT), normal prothrombin time (PT), and normal counts at screening period and at day -1 as defined by the local laboratory
  5. value ≥11.0 grams per deciliter (g/dL) for females and ≥12.9 g/dL for males at screening and day -1
  6. Negative fecal occult blood test (FOBT) during screening period
  7. Normal Bleeding time test (BTT) at day -1 as defined by the study site

Key Exclusion Criteria:

  1. History of any major surgical procedure or physical trauma, in the opinion of the investigator, that may pose a risk to the subject by study participation.
  2. Whole blood donation within the previous 56 days or plasma donation within the previous 7 days prior to screening
  3. Pregnant or breastfeeding women
  4. History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, neurological, or dermatologic disease, as assessed by the investigator
  5. Hospitalized for any reason within 30 days of the screening visit.
  6. Current smoker or former smoker, including e-cigarettes, who stopped smoking within 12 months prior to the screening visit
  7. Confirmed positive drug test result at the screening visit and/or prior to randomization or a history of drug abuse within a year prior to screening.
  8. History of alcohol abuse within the last 2 years prior to dosing
  9. Positive for (HIV), , or and/or per protocol resolved hepatitis B infection is not an exclusion.
  10. Any , except for nonmelanoma skin cancer or cervical/anus in situ, that have been resected with no evidence of disease for 3 years prior to the screening visit
  11. Women of child bearing potential (defined as women who are fertile, following menarche until becoming , unless permanently surgically sterile. The only allowed permanent sterilization methods for this study are hysterectomy and/or bilateral oophorectomy.)

Note: Other protocol defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Intravenous Cohorts

    Randomized 6:2 to REGN9933 or placebo

    Drug: REGN9933 · Drug: Placebo

  • Experimental
    Subcutaneous Cohorts

    Randomized 6:2 to REGN9933 or placebo

    Drug: REGN9933 · Drug: Placebo

Interventions

  • Administered intravenously (IV) or subcutaneous (SC) per the protocol

  • DrugPlacebo

    Placebo to match REGN9933 in same form; placebo administered IV or SC per the protocol

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment emergent adverse events (TEAE)

    Time frame: Until resolution of pharmacodynamic (PD) effects; approximately 36 days

Secondary outcomes

  1. Change from baseline in activated partial thromboplastin time (aPTT)

    Time frame: Until resolution of PD effects; approximately 36 days

  2. Change from baseline in prothrombin time (PT)

    Time frame: Until resolution of PD effects; approximately 36 days

  3. Concentration of REGN9933 in serum

    Time frame: Until resolution of PD effects; approximately 36 days

  4. Change from baseline in total Factor XI (FXI) concentrations

    Time frame: Until resolution of PD effects; approximately 36 days

  5. The incidence of antidrug antibodies (ADAs) to REGN9933 over time

    Time frame: Until resolution of PD effects; approximately 36 days

07

Study locations

1 site
  • Regeneron Study Site
    Edegem, Antwerp B-2650, Belgium
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Apr 2023, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2021
First posted
Nov 1, 2021
StartActual
Oct 27, 2021
Primary completionActual
Apr 4, 2023
CompletionActual
Apr 4, 2023
Last update
May 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05102136
Responsible party
Sponsor
First posted
Nov 1, 2021
Start date
Oct 27, 2021
Primary completion
Apr 4, 2023
Completion
Apr 4, 2023
Last update
May 3, 2023

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amrecibart

Start the discussion